It therefore remains an investigational medicinal product, available only within the context of authorised clinical trials
Administration of semaglutide at the dose regimen of ~ 90 g/kg/day failed to evidence significant weight loss but more importantly, led to alteration of cortical bone microarchitecture, represented by lower cortical thickness, and ultimately to a significant decrease in bone strength [69]
Behavior-first subscriptions and clinical-telehealth programs assemble cost differently, but as of April 2026 monthly totals across GLP-1 telehealth commonly range from roughly $200 to $700 or more, driven by the compound, plan length, and any coaching or membership layer
Medicare explicitly excludes weight loss medications from Part D coverage
Staying hydrated and avoiding excess alcohol can also improve how the body responds to the medication
doi: 10.1371/journal.pone.0058784 169 HansenHHFabriciusKBarkholtPNiehoffMLMorleyJEJelsingJet al